North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
|Articles|April 2, 2012
Dr. Farzad Mostashari Discusses Whether Payment Incentives for Achieving Meaningful Use is Enough
In this segment, Dr. Farzad Mostashari highlights both the financial and non-financial challenges providers face when implementing electronic medical records.
Advertisement
US Department of Health and Human Services
,
Farzad Mostashari, MD, ScM, National Coordinator for Health Information Technology, highlights both the financial and non-financial challenges providers face when implementing electronic medical records.
Advertisement
Related to this article
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
Advertisement
Advertisement